Glioblastoma is a fast-growing and aggressive brain cancer. It can invade and destroy healthy tissue, making it difficult to treat.
CAR-T therapy is a type of immunotherapy that reprograms a patient's immune cells to target cancer.
Researchers developed CAR-TEAM cells, combining CAR-T with T-cell engaging antibody molecules (TEAMs).
A phase 1 clinical trial tested CAR-TEAM cells on three patients with recurrent glioblastoma.
All three patients experienced significant tumor reduction after a single treatment.
The treatment response in one patient was sustained for over six months.
Dr. Bryan Choi: "This approach has the potential to be more effective against glioblastoma.
More research is needed to confirm its effectiveness and long-term benefits.